Crown Laboratories and Revance Announce Entry Into Merger Agreement

Go back to Crown Laboratories and Revance Announce Entry Into Merger Agreement

William Blair Downgrades Revance Therapeutic (RVNC) to Market Perform

August 12, 2024 11:12 AM EDT

William Blair analyst Tim Lugo downgraded Revance Therapeutic (NASDAQ: RVNC) from Outperform to Market Perform.

The analyst comments "Before the market open on Monday, August 12, Revance announced Crown Laboratories, a privately held, global leader in the skincare industry, will commence and... More

Stifel Downgrades Revance Therapeutic (RVNC) to Hold Following Go Private Deal

August 12, 2024 10:07 AM EDT

Stifel analyst Annabel Samimy downgraded Revance Therapeutic (NASDAQ: RVNC) from Buy to Hold with a price target of $6.66 (from $20.00).

The analyst comments "Surprising to us, RVNC announced this morning its intention to merge with Crown Laboratories, a privately-held, global skincare company for... More